Comprehensive overview of CJD including prion propagation, PRNP mutations, biomarkers, subtypes, and comparison with vCJD
Creutzfeldt-Jakob Disease (CJD) is the most common human prion disease, characterized by rapid progressive dementia, ataxia, myoclonus, and characteristic neuropathological findings including spongiform change, neuronal loss, and astrocytic gliosis. The disease results from the conformational conversion of the normal cellular prion protein (PrP^C) into the pathogenic isoform (PrP^Sc)[1].
CJD represents a unique category of neurodegenerative disease — it is the only condition known to be caused by a protein-only infectious agent (prion), which can be genetic, sporadic, or acquired. This mechanistic page covers prion propagation, genetic determinants, diagnostic biomarkers, and disease subtypes.
The prion protein is encoded by the PRNP gene on chromosome 20p13[2]:
| Property | Value |
|---|---|
| Gene | PRNP |
| Protein size | 253 amino acids |
| Molecular weight | ~33-35 kDa |
| Structure | Alpha-helix rich (N-terminal flexible, C-terminal globular) |
| Expression | Highest in CNS, widespread peripheral expression |
| Function | Proposed: copper binding, synaptic function, neuroprotection |
The scrapie isoform (PrP^Sc) differs from PrP^C in its:
The prion conversion mechanism involves[3]:
Over 50 pathogenic mutations in PRNP cause inherited prion diseases[4]:
| Mutation | Disease | Phenotype |
|---|---|---|
| P102L | GSS | Gerstmann-Sträussler-Scheinker syndrome |
| A117V | GSS | Ataxia, dementia |
| D178N | fCJD | Fatal familial insomnia + CJD |
| E200K | fCJD | Most common genetic CJD |
| V180I | fCJD | Japanese founder mutation |
| M232R | fCJD | Incomplete penetrance |
| Octapeptide insert | GSS | Variable phenotype |
Common polymorphisms modify CJD risk[5]:
| Polymorphism | Effect |
|---|---|
| M129V | Methionine (129M) increases sCJD risk |
| E219K | Glutamate (129E) reduces CJD risk |
| P101L | Associates with GSS |
The 129M/V polymorphism is particularly important:
Epidemiology[6]:
Classification by PRNP codon 129 and PrP^Sc type:
| Type | 129 Genotype | Clinicopathological Features |
|---|---|---|
| MM1 | MM | Most common (70%), classic presentation |
| VV2 | VV | Ataxic variant, cortical involvement |
| MV2 | MV | Intermediate, kuru-type plaques |
| MM2 | MM | cortical: slowly progressive; striatal: ataxia |
PRNP mutations cause ~10-15% of CJD cases[7]:
Transmission routes:
Characteristics[8]:
BSE connection[9]:
MRI findings:
EEG findings:
The 14-3-3 protein detection in CSF is a key diagnostic marker[11]:
| Feature | Value |
|---|---|
| Sensitivity | 94% for sCJD |
| Specificity | 75-85% (vs. other dementias) |
| Confounders | Recent seizures, infarction |
Mechanism: 14-3-3 proteins are released from damaged neurons
Real-Time Quaking-Induced Conversion is highly sensitive[12]:
| Feature | Value |
|---|---|
| Sensitivity | 88-95% |
| Specificity | 98-100% |
| Sample | CSF, nasal brushings |
| Time | 2-5 days |
Principle: Recombinant PrP substrate converts in presence of PrP^Sc seeds
| Biomarker | Description |
|---|---|
| Tau protein | Elevated in CSF, correlates with progression |
| S100B | Astrocyte damage marker |
| Neuronal-specific enolase | Neuronal loss marker |
| PrP^Sc in blood | Research stage, RT-QuIC on blood |
| Disease | Agent | Transmission | Key Features |
|---|---|---|---|
| sCJD | PrP^Sc | Sporadic | Rapid dementia, myoclonus |
| fCJD | PrP^Sc | Genetic (PRNP) | Family history |
| iCJD | PrP^Sc | Iatrogenic | Exposure history |
| vCJD | PrP^Sc | Dietary (BSE) | Young, psychiatric |
| GSS | PrP^Sc | Genetic | Ataxia, amyloid plaques |
| FFI | PrP^Sc | Genetic | Insomnia, autonomic failure |
| Feature | vCJD | sCJD |
|---|---|---|
| Age at onset | 20-40 years | 60-70 years |
| Disease duration | 12-14 months | 4-6 months |
| Onset type | Psychiatric/behavioral | Cognitive/motor |
| MRI | Prominent pulvinar sign | Cortical/basal ganglia |
| PrP plaques | Floral kuru-type | Rare |
FSE in cats is caused by BSE infection[13]:
No disease-modifying therapy exists. Supportive care is the mainstay:
| Approach | Status | Notes |
|---|---|---|
| Pentosan polysulfate | Negative | No survival benefit |
| Quinacrine | Negative | No clinical benefit |
| Flupirtine | Negative | Trial stopped |
| Antibiotics (doxycycline) | Mixed | Some positive signals |
| Strategy | Target | Stage |
|---|---|---|
| Anti-PrP antibodies | PrP^Sc | Preclinical |
| PrP^Sc aggregation inhibitors | PrP conversion | Preclinical |
| Gene silencing | PRNP expression | Research |
| Stem cell approaches | Neuronal replacement | Early research |
CJD represents the prototype of prion diseases — protein-misfolding disorders that can be sporadic, genetic, or infectious. The understanding of prion biology, developed over decades of research, has provided fundamental insights into other neurodegenerative diseases characterized by protein aggregation.
Key Takeaways:
PRNP gene structure and function. J Gen Virol. 2006. ↩︎
Prion protein conversion. Trends Biochem Sci. 2009. ↩︎
PRNP mutations and CJD. N Engl J Med. 1991. ↩︎
PRNP polymorphisms and CJD. Nat Rev Neurol. 2018. ↩︎
CJD surveillance and epidemiology. Nat Rev Neurol. 2023. ↩︎
Genetic CJD phenotypes. Brain. 2022. ↩︎
Variant CJD. Brain Pathol. 2013. ↩︎
vCJD and BSE. Lancet Neurol. 2009. ↩︎
vCJD blood transmission. Transfusion. 2012. ↩︎
14-3-3 proteins in CJD. Lancet Neurol. 2011. ↩︎
RT-QuIC in CJD diagnosis. Ann Neurol. 2017. ↩︎
Feline spongiform encephalopathy. Vet Res. 2014. ↩︎